Results: 10
#1
au:MORAES, JULIO C. B.
Filters
Order by
Page
of 1
Next
1.
Evaluation of the Seasonality and Extraction Method on the Polar Extracts of Croton grewioides Baill. by Chromatogram Fingerprinting and Isolation of a New Triglycosylated Flavonoid
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Prado, Vilma M. J.
; Jesus, Raphael A. de
; Oliveira, Julio M. A.
; Pereira, Camila S. A.
; Blank, Arie F.
; Pereira-Filho, Edenir R.
; Cass, Quezia B.
; Lima, Juliana M. de
; Ferreira, Antonio G.
; Nogueira, Paulo C. L.
; Moraes, Valéria R. S.
.
Croton grewioides Baill. popularly known as “canelinha” or “canelinha-de-cheiro” has been used for the treatment of influenza, antitussive, febrifuge and headache; however, the study of its phytochemical composition is limited. The aim of this study was to investigate the effect of the extraction method and seasonality through leaf extracts of four accessions of Croton grewioides by fingerprint chromatograms aided by principal component analysis to analyze the differences and similarities among the samples. We aimed also to provide chemical characterization of isolated secondary metabolites using semi-preparative liquid chromatography. The results showed that only the chemical profile of the methanolic extracts of accessions 101 and 113 were influenced by the seasonality. For the first time, four flavonoids were isolated through semi-preparative chromatography in this species, characterized as quercetin 3-O-β-D-galactopyranosyl-(1→2)-α-L-rhamnopyranoside-(1→6)-α-L-rhamnopyranoside (1), quercetin 3-O-β-D-galactopyranosyl-(1→2)-α-apiopyranoside-(1→6)-α-L-rhamnopyranoside (2), quercetin 3-O-glucopyranoside (3) and 3-O-methyl-quercetin (4), the flavonoid (2) has been recognized as a new triglycosylated derivative.
https://doi.org/10.21577/0103-5053.20200190
249 downloads
2.
Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Shimabuco, Andrea Y.
; Gonçalves, Celio R.
; Moraes, Julio C. B.
; Waisberg, Mariana G.
; Ribeiro, Ana Cristina de M.
; Sampaio-Barros, Percival D.
; Goldenstein-Schainberg, Claudia
; Bonfa, Eloisa
; Saad, Carla G. S.
.
Abstract Objective: To determine the clinical and demographic factors associated with disease remission and drug survival in patients with ankylosing spondylitis (AS) on TNF inhibitors. Methods: Data from a longitudinal electronic database of AS patients under anti-TNF therapy between June/2004 and August/2013. Demographic, clinical parameters, disease activity by ASDAS remission (< 1.3) and inactive/low (< 2.1) were analyzed to characterize reasons for drug survival and switching of anti-TNF. Results: Among 117 AS patients, 69 (59%) were prescribed only one anti-TNF, 48 (41%) switched to a second anti-TNF and 13 (11%) to a third anti-TNF. Considering ASDAS-CRP < 1.3, 31 (39%) patients were inactive at the end of the study. Non-switchers (P = 0.04), younger age (P = 0.004), non-smoking (P = 0.016), shorter disease duration (P = 0.047), more frequent use of SSZ (P = 0.037) and lower BASDAI (P = 0.027), BASMI (P = 0.034) and BASFI (P = 0.003) at baseline were associated with remission. In the multivariate analysis younger age (P = 0.016) and lower BASDAI (P = 0.032) remained as remission predictors. Conclusion: This study supports that ASDAS-CRP remission is an achievable goal not only for non-switchers but also for second anti-TNF, particularly in patients with younger age and lower BASDAI at baseline. Comedication and non-smoker status seems to have a beneficial effect in anti-TNF response in this population.
https://doi.org/10.1186/s42358-018-0040-x
648 downloads
3.
Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas - BiobadaBrasil)
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Yonekura, Claudia Leiko
; Oliveira, Rene Donizeti Ribeiro
; Titton, David C.
; Ranza, Roberto
; Ranzolin, Aline
; Hayata, André L.
; Duarte, Ângela
; Silveira, Inês G.
; Carvalho, Hellen M. da S. de
; Moraes, Júlio C. Bertacini de
; Abreu, Mirhelen Mendes de
; Valim, Valéria
; Bianchi, Washington
; Brenol, Claiton Viegas
; Pereira, Ivanio A.
; Costa, Izaias
; Macieira, José C.
; Miranda, José R.S.
; Guedes-Barbosa, Luiz S.
; Bertolo, Manoel B.
; Sauma, Maria Fátima Lobato da C.
; Silva, Marília B.G.
; Freire, Marlene
; Scheinberg, Morton A.
; Toledo, Roberto A.
; Oliveira, Sheila K.F.
; Fernandes, Vander
; Pinheiro, Marcelo M.
; Castro, Glaucio
; Vieira, Walber Pinto
; Baaklini, Cesar Emile
; Ruffino-Netto, Antonio
; Pinheiro, Geraldo da Rocha Castelar
; Laurindo, Ieda Maria Magalhães
; Louzada-Junior, Paulo
.
Resumo Objetivos Avaliar incidência de tuberculose e triagem para tuberculose latente em brasileiros com artrite reumatoide em uso de agentes biológicos na prática clinica. Pacientes e métodos Estudo de coorte com dados do Registro Brasileiro de Monitoração de Terapias Biológicas (BiobadaBrasil), de 01/2009 a 05/2013, abrangeu 1.552 tratamentos, 415 somente com drogas modificadoras do curso da doença (MMCDs) sintéticas, 942 MMCDs sintéticas em associação com anti-TNF (etanercepte, infliximabe, adalimumabe) e 195 MMCDs sintéticas em associação com outros biológicos (abatacepte, rituximabe e tocilizumabe). Avaliaram-se ocorrência de tuberculose, tempo de exposição às drogas e triagem para TB. Análise estatística: teste t não pareado e teste de Fisher bicaudal; p < 0,05. Resultados O tempo de exposição dos controles foi de 981 pacientes-ano, do grupo de anti-TNF foi de 1.744 pacientes-ano (adalimumabe = 676, infliximabe = 547 e etanercepte = 521 pacientes-ano) e o de outros biológicos de 336 pacientes-ano. A incidência de TB foi de 1,01/1.000 pacientes-ano nos controles e de 2,87 pacientes-ano nos usuários de anti-TNF (adalimumabe = 4,43/1.000 pacientes-ano; etanercepte = 1,92/1.000 pacientes-ano e infliximabe = 1,82/1.000 pacientes-ano). Não houve casos de tuberculose no grupo de outros biológicos. O tempo médio de exposição até a ocorrência de tuberculose foi de 27(11) meses para o grupo anti-TNF. Conclusões A incidência de tuberculose foi maior nos usuários de MMCDs sintéticas e anti-TNF do que nos usuários de MMCDs sintéticas e de MMCDs sintéticas e biológicos não anti-TNF, e também mais tardia, sugerindo infecção durante o tratamento, e não falha na triagem.
Abstract Objectives To assess the incidence of tuberculosis and to screen for latent tuberculosis infection among Brazilians with rheumatoid arthritis using biologics in clinical practice. Patients and methods This cohort study used data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas - BiobadaBrasil), from 01/2009 to 05/2013, encompassing 1552 treatments, including 415 with only synthetic disease-modifying anti-rheumatic drugs, 942 synthetic DMARDs combined with anti-tumor necrosis factor (etanercept, infliximab, adalimumab) and 195 synthetic DMARDs combined with other biologics (abatacept, rituximab and tocilizumab). The occurrence of tuberculosis and the drug exposure time were assessed, and screening for tuberculosis was performed. Statistical analysis: Unpaired t-test and Fisher's two-tailed test; p < 0.05. Results The exposure times were 981 patient-years in the controls, 1744 patient-years in the anti-TNF group (adalimumab = 676, infliximab = 547 and etanercept = 521 patient-years) and 336 patient-years in the other biologics group. The incidence rates of tuberculosis were 1.01/1000 patient-years in the controls and 2.87 patient-years among anti-TNF users (adalimumab = 4.43/1000 patient-years; etanercept = 1.92/1000 patient-years and infliximab = 1.82/1000 patient-years). No cases of tuberculosis occurred in the other biologics group. The mean drug exposure time until the occurrence of tuberculosis was 27(11) months for the anti-TNF group. Conclusions The incidence of tuberculosis was higher among users of synthetic DMARDs and anti-TNF than among users of synthetic DMARDs and synthetic DMARDs and non-anti-TNF biologics and also occurred later, suggesting infection during treatment and no screening failure.
https://doi.org/10.1016/j.rbre.2017.05.005
3602 downloads
4.
Growing knowledge: an overview of Seed Plant diversity in Brazil
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Zappi, Daniela C.
; Filardi, Fabiana L. Ranzato
; Leitman, Paula
; Souza, Vinícius C.
; Walter, Bruno M.T.
; Pirani, José R.
; Morim, Marli P.
; Queiroz, Luciano P.
; Cavalcanti, Taciana B.
; Mansano, Vidal F.
; Forzza, Rafaela C.
; Abreu, Maria C.
; Acevedo-Rodríguez, Pedro
; Agra, Maria F.
; Almeida Jr., Eduardo B.
; Almeida, Gracineide S.S.
; Almeida, Rafael F.
; Alves, Flávio M.
; Alves, Marccus
; Alves-Araujo, Anderson
; Amaral, Maria C.E.
; Amorim, André M.
; Amorim, Bruno
; Andrade, Ivanilza M.
; Andreata, Regina H.P.
; Andrino, Caroline O.
; Anunciação, Elisete A.
; Aona, Lidyanne Y.S.
; Aranguren, Yani
; Aranha Filho, João L.M.
; Araújo, Andrea O.
; Araújo, Ariclenes A.M.
; Araújo, Diogo
; Arbo, María M.
; Assis, Leandro
; Assis, Marta C.
; Assunção, Vivian A.
; Athiê-Souza, Sarah M.
; Azevedo, Cecilia O.
; Baitello, João B.
; Barberena, Felipe F.V.A.
; Barbosa, Maria R.V.
; Barros, Fábio
; Barros, Lucas A.V.
; Barros, Michel J.F.
; Baumgratz, José F.A.
; Bernacci, Luis C.
; Berry, Paul E.
; Bigio, Narcísio C.
; Biral, Leonardo
; Bittrich, Volker
; Borges, Rafael A.X.
; Bortoluzzi, Roseli L.C.
; Bove, Cláudia P.
; Bovini, Massimo G.
; Braga, João M.A.
; Braz, Denise M.
; Bringel Jr., João B.A.
; Bruniera, Carla P.
; Buturi, Camila V.
; Cabral, Elza
; Cabral, Fernanda N.
; Caddah, Mayara K.
; Caires, Claudenir S.
; Calazans, Luana S.B.
; Calió, Maria F.
; Camargo, Rodrigo A.
; Campbell, Lisa
; Canto-Dorow, Thais S.
; Carauta, Jorge P.P.
; Cardiel, José M.
; Cardoso, Domingos B.O.S.
; Cardoso, Leandro J.T.
; Carneiro, Camila R.
; Carneiro, Cláudia E.
; Carneiro-Torres, Daniela S.
; Carrijo, Tatiana T.
; Caruzo, Maria B.R.
; Carvalho, Maria L.S.
; Carvalho-Silva, Micheline
; Castello, Ana C.D.
; Cavalheiro, Larissa
; Cervi, Armando C.
; Chacon, Roberta G.
; Chautems, Alain
; Chiavegatto, Berenice
; Chukr, Nádia S.
; Coelho, Alexa A.O.P.
; Coelho, Marcus A.N.
; Coelho, Rubens L.G.
; Cordeiro, Inês
; Cordula, Elizabeth
; Cornejo, Xavier
; Côrtes, Ana L.A.
; Costa, Andrea F.
; Costa, Fabiane N.
; Costa, Jorge A.S.
; Costa, Leila C.
; Costa-e-Silva, Maria B.
; Costa-Lima, James L.
; Cota, Maria R.C.
; Couto, Ricardo S.
; Daly, Douglas C.
; De Stefano, Rodrigo D.
; De Toni, Karen
; Dematteis, Massimiliano
; Dettke, Greta A.
; Di Maio, Fernando R.
; Dórea, Marcos C.
; Duarte, Marília C.
; Dutilh, Julie H.A.
; Dutra, Valquíria F.
; Echternacht, Lívia
; Eggers, Lilian
; Esteves, Gerleni
; Ezcurra, Cecilia
; Falcão Junior, Marcus J.A.
; Feres, Fabíola
; Fernandes, José M.
; Ferreira, D.M.C.
; Ferreira, Fabrício M.
; Ferreira, Gabriel E.
; Ferreira, Priscila P.A.
; Ferreira, Silvana C.
; Ferrucci, Maria S.
; Fiaschi, Pedro
; Filgueiras, Tarciso S.
; Firens, Marcela
; Flores, Andreia S.
; Forero, Enrique
; Forster, Wellington
; Fortuna-Perez, Ana P.
; Fortunato, Reneé H.
; Fraga, Cléudio N.
; França, Flávio
; Francener, Augusto
; Freitas, Joelcio
; Freitas, Maria F.
; Fritsch, Peter W.
; Furtado, Samyra G.
; Gaglioti, André L.
; Garcia, Flávia C.P.
; Germano Filho, Pedro
; Giacomin, Leandro
; Gil, André S.B.
; Giulietti, Ana M.
; A.P.Godoy, Silvana
; Goldenberg, Renato
; Gomes da Costa, Géssica A.
; Gomes, Mário
; Gomes-Klein, Vera L.
; Gonçalves, Eduardo Gomes
; Graham, Shirley
; Groppo, Milton
; Guedes, Juliana S.
; Guimarães, Leonardo R.S.
; Guimarães, Paulo J.F.
; Guimarães, Elsie F.
; Gutierrez, Raul
; Harley, Raymond
; Hassemer, Gustavo
; Hattori, Eric K.O.
; Hefler, Sonia M.
; Heiden, Gustavo
; Henderson, Andrew
; Hensold, Nancy
; Hiepko, Paul
; Holanda, Ana S.S.
; Iganci, João R.V.
; Imig, Daniela C.
; Indriunas, Alexandre
; Jacques, Eliane L.
; Jardim, Jomar G.
; Kamer, Hiltje M.
; Kameyama, Cíntia
; Kinoshita, Luiza S.
; Kirizawa, Mizué
; Klitgaard, Bente B.
; Koch, Ingrid
; Koschnitzke, Cristiana
; Krauss, Nathália P.
; Kriebel, Ricardo
; Kuntz, Juliana
; Larocca, João
; Leal, Eduardo S.
; Lewis, Gwilym P.
; Lima, Carla T.
; Lima, Haroldo C.
; Lima, Itamar B.
; Lima, Laíce F.G.
; Lima, Laura C.P.
; Lima, Leticia R.
; Lima, Luís F.P.
; Lima, Rita B.
; Lírio, Elton J.
; Liro, Renata M.
; Lleras, Eduardo
; Lobão, Adriana
; Loeuille, Benoit
; Lohmann, Lúcia G.
; Loiola, Maria I.B.
; Lombardi, Julio A.
; Longhi-Wagner, Hilda M.
; Lopes, Rosana C.
; Lorencini, Tiago S.
; Louzada, Rafael B.
; Lovo, Juliana
; Lozano, Eduardo D.
; Lucas, Eve
; Ludtke, Raquel
; Luz, Christian L.
; Maas, Paul
; Machado, Anderson F.P.
; Macias, Leila
; Maciel, Jefferson R.
; Magenta, Mara A.G.
; Mamede, Maria C.H.
; Manoel, Evelin A.
; Marchioretto, Maria S.
; Marques, Juliana S.
; Marquete, Nilda
; Marquete, Ronaldo
; Martinelli, Gustavo
; Martins da Silva, Regina C.V.
; Martins, Ângela B.
; Martins, Erika R.
; Martins, Márcio L.L.
; Martins, Milena V.
; Martins, Renata C.
; Matias, Ligia Q.
; Maya-L., Carlos A.
; Mayo, Simon
; Mazine, Fiorella
; Medeiros, Debora
; Medeiros, Erika S.
; Medeiros, Herison
; Medeiros, João D.
; Meireles, José E.
; Mello-Silva, Renato
; Melo, Aline
; Melo, André L.
; Melo, Efigênia
; Melo, José I.M.
; Menezes, Cristine G.
; Menini Neto, Luiz
; Mentz, Lilian A.
; Mezzonato, A.C.
; Michelangeli, Fabián A.
; Milward-de-Azevedo, Michaele A.
; Miotto, Silvia T.S.
; Miranda, Vitor F.O.
; Mondin, Cláudio A.
; Monge, Marcelo
; Monteiro, Daniele
; Monteiro, Raquel F.
; Moraes, Marta D.
; Moraes, Pedro L.R.
; Mori, Scott A.
; Mota, Aline C.
; Mota, Nara F.O.
; Moura, Tania M.
; Mulgura, Maria
; Nakajima, Jimi N.
; Nardy, Camila
; Nascimento Júnior, José E.
; Noblick, Larry
; Nunes, Teonildes S.
; O'Leary, Nataly
; Oliveira, Arline S.
; Oliveira, Caetano T.
; Oliveira, Juliana A.
; Oliveira, Luciana S.D.
; Oliveira, Maria L.A.A.
; Oliveira, Regina C.
; Oliveira, Renata S.
; Oliveira, Reyjane P.
; Paixão-Souza, Bruno
; Parra, Lara R.
; Pasini, Eduardo
; Pastore, José F.B.
; Pastore, Mayara
; Paula-Souza, Juliana
; Pederneiras, Leandro C.
; Peixoto, Ariane L.
; Pelissari, Gisela
; Pellegrini, Marco O.O.
; Pennington, Toby
; Perdiz, Ricardo O.
; Pereira, Anna C.M.
; Pereira, Maria S.
; Pereira, Rodrigo A.S.
; Pessoa, Clenia
; Pessoa, Edlley M.
; Pessoa, Maria C.R.
; Pinto, Luiz J.S.
; Pinto, Rafael B.
; Pontes, Tiago A.
; Prance, Ghillean T.
; Proença, Carolyn
; Profice, Sheila R.
; Pscheidt, Allan C.
; Queiroz, George A.
; Queiroz, Rubens T.
; Quinet, Alexandre
; Rainer, Heimo
; Ramos, Eliana
; Rando, Juliana G.
; Rapini, Alessandro
; Reginato, Marcelo
; Reis, Ilka P.
; Reis, Priscila A.
; Ribeiro, André R.O.
; Ribeiro, José E.L.S.
; Riina, Ricarda
; Ritter, Mara R.
; Rivadavia, Fernando
; Rocha, Antônio E.S.
; Rocha, Maria J.R.
; Rodrigues, Izabella M.C.
; Rodrigues, Karina F.
; Rodrigues, Rodrigo S.
; Rodrigues, Rodrigo S.
; Rodrigues, Vinícius T.
; Rodrigues, William
; Romaniuc Neto, Sérgio
; Romão, Gerson O.
; Romero, Rosana
; Roque, Nádia
; Rosa, Patrícia
; Rossi, Lúcia
; Sá, Cyl F.C.
; Saavedra, Mariana M.
; Saka, Mariana
; Sakuragui, Cássia M.
; Salas, Roberto M.
; Sales, Margareth F.
; Salimena, Fatima R.G.
; Sampaio, Daniela
; Sancho, Gisela
; Sano, Paulo T.
; Santos, Alessandra
; Santos, Élide P.
; Santos, Juliana S.
; Santos, Marianna R.
; Santos-Gonçalves, Ana P.
; Santos-Silva, Fernanda
; São-Mateus, Wallace
; Saraiva, Deisy P.
; Saridakis, Dennis P.
; Sartori, Ângela L.B.
; Scalon, Viviane R.
; Schneider, Ângelo
; Sebastiani, Renata
; Secco, Ricardo S.
; Senna, Luisa
; Senna-Valle, Luci
; Shirasuna, Regina T.
; Silva Filho, Pedro J.S.
; Silva, Anádria S.
; Silva, Christian
; Silva, Genilson A.R.
; Silva, Gisele O.
; Silva, Márcia C.R.
; Silva, Marcos J.
; Silva, Marcos J.
; Silva, Otávio L.M.
; Silva, Rafaela A.P.
; Silva, Saura R.
; Silva, Tania R.S.
; Silva-Gonçalves, Kelly C.
; Silva-Luz, Cíntia L.
; Simão-Bianchini, Rosângela
; Simões, André O.
; Simpson, Beryl
; Siniscalchi, Carolina M.
; Siqueira Filho, José A.
; Siqueira, Carlos E.
; Siqueira, Josafá C.
; Smith, Nathan P.
; Snak, Cristiane
; Soares Neto, Raimundo L.
; Soares, Kelen P.
; Soares, Marcos V.B.
; Soares, Maria L.
; Soares, Polyana N.
; Sobral, Marcos
; Sodré, Rodolfo C.
; Somner, Genise V.
; Sothers, Cynthia A.
; Sousa, Danilo J.L.
; Souza, Elnatan B.
; Souza, Élvia R.
; Souza, Marcelo
; Souza, Maria L.D.R.
; Souza-Buturi, Fátima O.
; Spina, Andréa P.
; Stapf, María N.S.
; Stefano, Marina V.
; Stehmann, João R.
; Steinmann, Victor
; Takeuchi, Cátia
; Taylor, Charlotte M.
; Taylor, Nigel P.
; Teles, Aristônio M.
; Temponi, Lívia G.
; Terra-Araujo, Mário H.
; Thode, Veronica
; Thomas, W.Wayt
; Tissot-Squalli, Mara L.
; Torke, Benjamin M.
; Torres, Roseli B.
; Tozzi, Ana M.G.A.
; Trad, Rafaela J.
; Trevisan, Rafael
; Trovó, Marcelo
; Valls, José F.M.
; Vaz, Angela M.S.F.
; Versieux, Leonardo
; Viana, Pedro L.
; Vianna Filho, Marcelo D.M.
; Vieira, Ana O.S.
; Vieira, Diego D.
; Vignoli-Silva, Márcia
; Vilar, Thaisa
; Vinhos, Franklin
; Wallnöfer, Bruno
; Wanderley, Maria G.L.
; Wasshausen, Dieter
; Watanabe, Maurício T.C.
; Weigend, Maximilian
; Welker, Cassiano A.D.
; Woodgyer, Elizabeth
; Xifreda, Cecilia C.
; Yamamoto, Kikyo
; Zanin, Ana
; Zenni, Rafael D.
; Zickel, Carmem S
.
Resumo Um levantamento atualizado das plantas com sementes e análises relevantes acerca desta biodiversidade são apresentados. Este trabalho se iniciou em 2010 com a publicação do Catálogo de Plantas e Fungos e, desde então vem sendo atualizado por mais de 430 especialistas trabalhando online. O Brasil abriga atualmente 32.086 espécies nativas de Angiospermas e 23 espécies nativas de Gimnospermas e estes novos dados mostram um aumento de 3% da riqueza em relação a 2010. A Amazônia é o Domínio Fitogeográfico com o maior número de espécies de Gimnospermas, enquanto que a Floresta Atlântica possui a maior riqueza de Angiospermas. Houve um crescimento considerável no número de espécies e nas taxas de endemismo para a maioria dos Domínios (Caatinga, Cerrado, Floresta Atlântica, Pampa e Pantanal), com exceção da Amazônia que apresentou uma diminuição de 2,5% de endemicidade. Entretanto, a maior parte das plantas com sementes que ocorrem no Brasil (57,4%) é endêmica deste território. A proporção de formas de vida varia de acordo com os diferentes Domínios: árvores são mais expressivas na Amazônia e Floresta Atlântica do que nos outros biomas, ervas são dominantes no Pampa e as lianas apresentam riqueza expressiva na Amazônia, Floresta Atlântica e Pantanal. Este trabalho não só quantifica a biodiversidade brasileira, mas também indica as lacunas de conhecimento e o desafio a ser enfrentado para a conservação desta flora.
Abstract An updated inventory of Brazilian seed plants is presented and offers important insights into the country's biodiversity. This work started in 2010, with the publication of the Plants and Fungi Catalogue, and has been updated since by more than 430 specialists working online. Brazil is home to 32,086 native Angiosperms and 23 native Gymnosperms, showing an increase of 3% in its species richness in relation to 2010. The Amazon Rainforest is the richest Brazilian biome for Gymnosperms, while the Atlantic Rainforest is the richest one for Angiosperms. There was a considerable increment in the number of species and endemism rates for biomes, except for the Amazon that showed a decrease of 2.5% of recorded endemics. However, well over half of Brazillian seed plant species (57.4%) is endemic to this territory. The proportion of life-forms varies among different biomes: trees are more expressive in the Amazon and Atlantic Rainforest biomes while herbs predominate in the Pampa, and lianas are more expressive in the Amazon, Atlantic Rainforest, and Pantanal. This compilation serves not only to quantify Brazilian biodiversity, but also to highlight areas where there information is lacking and to provide a framework for the challenge faced in conserving Brazil's unique and diverse flora.
https://doi.org/10.1590/2175-7860201566411
33340 downloads
5.
Efeitos da associação de tiletamina/zolazepam ou cetamina S(+)/midazolam/tramadol para contenção química em bugios-ruivos (Allouatta guariba clamitans)
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Spolti, Pâmela
; Moraes, Aury N. de
; Tamanho, Renato B.
; Gehrcke, Martielo I.
; Souza Júnior, Júlio C.
; Oleskovicz, Nilson
.
Avaliaram-se dois protocolos para contenção química em bugios-ruivos. Para tal, foram utilizados 12 macacos bugios, hígidos, com peso médio de 6,4±0,4 kg, os quais foram submetidos a jejum alimentar e hídrico de seis e duas horas, respectivamente. Os animais foram alocados em dois grupos que receberam injeção via intramuscular: TZ (n=6), os quais receberam uma associação de tiletamina e zolazepam (Zoletil®) na dose de 3,6mg/kg e CEMTRA (n=6), que receberam cetamina S(+), midazolam e tramadol (Cemtra ®, lote piloto 001/10, Ouro Fino Saúde Animal Ltda., Cravinhos, SP-Brasil, constituído por 100mg/ml de cetamina S+, 20mg/ml de tramadol e 10mg/ml de midazolam) na dose de 1ml da associação para cada 10kg de peso corporal, correspondendo às doses de 10mg/kg, 1mg/kg e 2mg/kg, respectivamente. Anteriormente a administração dos fármacos (M0) foram avaliadas: frequência cardíaca (FC) e respiratória (f), temperatura retal (TR), tempo de preenchimento capilar (TPC), pressão arterial sistólica (PAS), saturação de oxigênio na hemoglobina (SpO2), presença de salivação, grau de miorrelaxamento e sedação, índice Bispectral (BIS) e Sinal de Qualidade do BIS (SQI), resposta ao pinçamento interdigital e tempos de latência, deambulação e de recuperação total (TRT). Os parâmetros foram reavaliados em M5, M10, M20, M30, M40 e M50 (5, 10, 20, 30, 40 e 50 minutos após a administração dos fármacos). No TZ os animais foram mais responsivos ao pinçamento interdigital ao longo dos tempos. Os animais do CEMTRA apresentaram maior grau de miorrelaxamento e de sedação. A f do CEMTRA foi menor após a administração do tratamento em todos os momentos em relação ao M0. Entre grupos a f do CEMTRA foi menor em relação ao TZ em M2 e M4. Os tempos totais de sedação e de recuperação foram de 48±4 e 150,1±42,1 min para o CEMTRA e de 38±7 e 73,1±20,6 para o TZ. Conclui-se que ambas as formulações são seguras para contenção química de bugios, sendo que o CEMTRA apresentou melhor sedação e miorrelaxamento.
Two protocols for chemical restraint in howler-redheads were evaluated. We used 12 healthy red howler monkeys, weighing 6.4±0.4 kg, which were fasted and without water six and two hours, respectively. The animals were divided into two groups that received intramuscular injection: TZ (n=6) which received tiletamine-zolazepam (Zoletil®) at a dose of 3.6mg/kg and CEMTRA (n=6) which received ketamine S (+), tramadol and midazolan (Cemtra®, pilot batch 001/10, Ouro Fino Saúde Animal Ltda, Cravinhos/SP, Brazil, comprising 100mg/ml of ketamine S (+), tramadol 20mg/ml and 10mg/ml of midazolam) in dose of 1ml of the association for each 10kg of body weight, equivalent doses of 10mg/kg, 1mg/kg and 2mg/kg, respectively. Prior to administration of drugs (M0) were evaluated: heart rate (HR), respiratory rate (RR), rectal temperature (RT), capillary refill time (CRT), systolic arterial pressure (SAP), hemoglobin oxygen saturation (SpO2 ), presence of salivation, degree of muscle relaxation and sedation, Bispectral index (BIS) and Signal Quality BIS (SQI), interdigital pinch response and latency times, ambulation and total recovery (TRT). The parameters were reassessed M5, M10, M20, M30, M40 and M50 (5, 10, 20, 30, 40 and 50 minutes after drug administration). In TZ animals were more responsive to the interdigital pinch over time. The animals of CEMTRA showed a higher degree of muscle relaxation and sedation. The RR of CEMTRA was lower after administration of treatment at all times in relation to M0. Among the groups RR of CEMTRA was lower compared to the TZ in M2 and M4. The total time of sedation and recovery was 48±4 min and 150.1±42.1 for the CEMTRA and 38±7 and 73.1±20.6 for the TZ. We conclude that both formulations are safe for containing chemical howler, and the CEMTRA showed better sedation and muscle relaxant.
7117 downloads
6.
Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Miossi, Renata
; Fuller, Ricardo
; Moraes, Júlio C. B.
; Ribeiro, Ana Cristina M.
; Saad, Carla G. S.
; Aikawa, Nadia E.
; Miraglia, Joao L.
; Ishida, Maria A.
; Bonfa, Eloisa
; Caleiro, M. Teresa C.
.
OBJECTIVE: To assess the potential acute effects regarding the immunogenicity and safety of non-adjuvanted influenza A H1N1/2009 vaccine in patients with mixed connective tissue disease and healthy controls. METHODS: Sixty-nine mixed connective tissue disease patients that were confirmed by Kasukawa's classification criteria and 69 age- and gender-matched controls participated in the study; the participants were vaccinated with the non-adjuvanted influenza A/California/7/2009 (H1N1) virus-like strain. The percentages of seroprotec-tion, seroconversion, geometric mean titer and factor increase in the geometric mean titer were calculated. The patients were clinically evaluated, and blood samples were collected pre- and 21 days post-vaccination to evaluate C-reactive protein, muscle enzymes and autoantibodies. Anti-H1N1 titers were determined using an influenza hemagglutination inhibition assay. ClinicalTrials.gov: NCT01151644. RESULTS: Before vaccination, no difference was observed regarding the seroprotection rates (p = 1.0) and geometric mean titer (p = 0.83) between the patients and controls. After vaccination, seroprotection (75.4% vs. 71%, (p = 0.7), seroconversion (68.1% vs. 65.2%, (p = 1.00) and factor increase in the geometric mean titer (10.0 vs. 8.0, p = 0.40) were similar in the two groups. Further evaluation of seroconversion in patients with and without current or previous history of muscle disease (p = 0.20), skin ulcers (p = 0.48), lupus-like cutaneous disease (p = 0.74), secondary Sjogren syndrome (p = 0.78), scleroderma-pattern in the nailfold capillaroscopy (p = 1.0), lymphopenia #1000/mm³ on two or more occasions (p = 1.0), hypergammaglobulinemia $1.6 g/d (p = 0.60), pulmonary hypertension (p = 1.0) and pulmonary fibrosis (p = 0.80) revealed comparable rates. Seroconversion rates were also similar in patients with and without immunosuppressants. Disease parameters, such as C-reactive protein (p = 0.94), aldolase (p = 0.73), creatine phosphokinase (p = 0.40) and ribonucleoprotein antibody levels (p = 0.98), remained largely unchanged pre and post-vaccination. No severe side effects were reported. CONCLUSIONS: The non-adjuvanted influenza A/H1N1 vaccination immune response in mixed connective tissue disease patients is adequate and does not depend on the disease manifestations and therapy.
https://doi.org/10.6061/CLINICS/2013(02)OA02
2000 downloads
7.
Terapia celular no diabetes mellitus
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Voltarelli, Julio C.
; Couri, Carlos E. B.
; Rodrigues, Maria Carolina
; Moraes, Daniela A.
; Stracieri, Ana Beatriz P. L.
; Pieroni, Fabiano
; Navarro, George
; Madeira, Maria Isabel A.
; Simões, Belinda P.
.
Revista Brasileira de Hematologia e Hemoterapia
- Journal Metrics
Nesta revisão são discutidas várias alternativas de regeneração do conjunto de células produtoras de insulina do pâncreas, usando células-tronco embrionárias do cordão umbilical e adultas, e o trabalho que está sendo realizado em nosso grupo de pesquisas utilizando imunossupressão em altas doses combinada com a infusão de células-tronco hematopoéticas autólogas em diabete do tipo 1 recém-diagnosticado.
In this review, we discuss several alternatives for the regeneration of the pool of insulin-producing cells by the pancreas using embryonic, cord blood or adult stem cells and the work being carried out by our research group using high dose immunosuppression with autologous hematopoietic stem cells in newly diagnosed type 1 diabetes mellitus.
10780 downloads
8.
The role of hematopoietic stem cell transplantation for type 1 diabetes mellitus
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Voltarelli, Júlio C.
; Couri, Carlos Eduardo B.
; Rodrigues, Maria Carolina
; Stracieri, Ana Beatriz P. L.
; Moraes, Daniela A.
; Pieroni, Fabiano
; Navarro, George
; Madeira, Maria Isabel A.
; Simões, Belinda P.
.
Revista Brasileira de Hematologia e Hemoterapia
- Journal Metrics
Nesta revisão, são apresentadas: 1) as bases científicas para o uso de imunossupressão em alta dose seguida de transplante autólogo de células-tronco hematopoéticas do sangue periférico no diabete melito do tipo 1 recém-diagnosticado; 2) uma atualização da evolução clínica e laboratorial de 21 pacientes transplantados no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, da Universidade de São Paulo, Brasil, incluindo recaídas em seis pacientes transplantados sem cetoacidose prévia; e 3) uma discussão das perspectivas futuras de terapia celular no diabete melito do tipo 1.
In this review, we present 1) scientific basis for the use of high dose immunosuppression followed by autologous peripheral blood hematopoietic stem cell transplantation for newly diagnosed type 1 diabetes mellitus, 2) an update of clinical and laboratory outcomes in 21 patients transplanted at the University Hospital of the Ribeirão Preto Medical School, University of São Paulo, Brazil, including 6 relapses in patients without previous ketoacidosis and 3) a discussion of future prospectives of cellular therapy for type 1 diabetes mellitus.
3742 downloads
9.
Transplante de células-tronco hematopoéticas em doenças reumáticas. Parte 2: experiência brasileira e perspectivas futuras
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Voltarelli, Júlio C.
; Stracieri, Ana Beatriz P. L.
; Oliveira, Maria Carolina B.
; Godoi, Dannielle F.
; Moraes, Daniela A.
; Pieroni, Fabiano
; Malmegrim, Kelen C. R.
; Coutinho, Marina A.
; Simões, Belinda P.
; Massumoto, Celso
; Hamerschlak, Nelson
; Scheinberg, Morton
; Ferreira, Eurípides
; Coutinho, Mariana
; Ostronoff, Maurício
; Sturaro, Daniel
; Dulley, Frederico
.
Nesta revisão, discutem-se os resultados dos transplantes de células-tronco hematopoéticas (TCTH) para doenças reumáticas graves e refratárias à terapia convencional realizados no Brasil. São analisados os resultados preliminares obtidos no Brasil com o TCTH autólogo em casos esporádicos (N=3) e no protocolo cooperativo iniciado em 2001 (N=18). Neste protocolo, dentre os 8 casos de nefrite lúpica, houve 3 remissões sustentadas, 3 óbitos, 1 falha de mobilização e 1 seguimento ainda muito curto; entre os 7 de esclerose sistêmica, houve 3 remissões após o TCTH e 2 após mobilização, um óbito pós-mobilização das CTH e outro após a primeira dose do condicionamento, este último em uma superposição com LES; em dois pacientes com vasculite, houve uma remissão em arterite de Takayasu e outra em doença de Behçet; uma paciente com artrite inflamatória juvenil foi incluída muito recentemente no protocolo. O seguimento dos pacientes sobreviventes variou de 0 a 48 meses, com uma mediana de 29 meses. Conclui-se com uma discussão do custo-benefício do TCTH em face das novas formas de imunossupressão disponíveis e das perspectivas futuras em países desenvolvidos, onde se iniciaram recentemente estudos prospectivos randomizados comparando o transplante com a melhor terapia medicamentosa disponível, e no Brasil, onde o custo do transplante é muito inferior ao das novas terapias biológicas.
In this review, we discuss the results of hematopoietic stem cell transplantation (HSCT) for severe and refractory rheumatic diseases performed in Brazil. We analyze preliminary results obtained in Brazil with autologous HSCT in anecdotal cases (N = 3) and in the cooperative protocol initiated in 2001 (N = 18). In 8 lupus nephritis patients there were 3 sustained remissions, 3 deaths, 1 mobilisation failure and 1 short follow-up; in 7 systemic sclerosis patients there were 3 sustained remissions after transplantation and 2 after mobilisation, 1 death before mobilisation and another after the first dose of the conditioning in an overlapping syndrome of SLE and SSc, and between 2 patients with vasculitis there was 1 sustained remission in Takayasu's arteritis and another in Behçet's disease. One patient with juvenile idiopathic arthritis was included in the protocol very recently. The follow-up of the patients varied from 0 to 48 months with a median of 29 months. We conclude the study with a discussion of future prospectives in developed countries, where randomized trials comparing transplantation with the best pharmacological therapy available have started recently, and in Brazil, where several adaptations of existing protocols are required and the cost of transplantation is much lower than that of new biological therapies.
6623 downloads
10.
Transplante de células-tronco hematopoéticas em doenças reumáticas parte 1: experiência internacional
Facebook Twitter
Facebook Twitter
- Other social networks
- Google+
- StambleUpon
- CiteULike
- Mendeley
- Other networks
- Metrics
Voltarelli, Júlio C.
; Stracieri, Ana Beatriz P. L.
; Oliveira, Maria Carolina B.
; Godoi, Dannielle F.
; Moraes, Daniela A.
; Pieroni, Fabiano
; Malmegrim, Kelen C. R.
; Coutinho, Marina A.
; Simões, Belinda P.
.
Nesta revisão, discutem-se os resultados dos transplantes de células-tronco hematopoéticas (TCTH) para doenças reumáticas graves e refratárias à terapia convencional realizados no exterior. Revêem-se brevemente as bases clínicas e experimentais para a realização desses transplantes e os resultados internacionais obtidos em lúpus eritematoso sistêmico (LES) (33/50 remissões completas no registro europeu, com dez recidivas posteriores e 12 óbitos; 41/45 remissões duradouras em um centro americano, com dois óbitos pós-mobilização e quatro óbitos pós-transplante), artrite reumatóide (AR) do adulto (58/73 remissões parciais com 85% de recidivas posteriores e apenas um óbito no registro europeu), artrite idiopática juvenil (AIJ) (18/34 remissões duradouras e cinco óbitos no registro europeu), esclerose sistêmica (ES) (46/50 respostas em um estudo europeu multicêntrico, com 35% de recidivas e 23% de mortalidade, enquanto num estudo americano, houve quatro óbitos e duas pneumopatias progressivas dentre 19 pacientes e melhora cutânea e da qualidade de vida em todos os sobreviventes) e em uma miscelânea de outras doenças, incluindo as vasculites (9/15 respostas completas no registro europeu). Conclui-se que, na experiência internacional, o TCTH autólogo induz remissões prolongadas na maioria das doenças graves e refratárias em que foi utilizado, com exceção da AR do adulto, justificando o início de estudos prospectivos randomizados comparando-o com a terapia convencional otimizada.
In this review, we discuss the results of hematopoietic stem cell transplantation (HSCT) for severe and refractory rheumatic diseases performed abroad. We briefly review clinical and experimental basis for those transplants and the international results obtained in systemic lupus erythematosus (SLE) (33/50 complete remissions in the European registry with 10 relapses and 12 deaths, and 41 durable remissions in an American study with 2 deaths post-mobilisation and 4 deaths posttransplantation), adult rheumatoid arthritis (58/73 partial remissions with 85% of relapses and only one death in the European registry), juvenile idiopathic arthritis (18/34 durable remissions and 5 deaths in the European registry), systemic sclerosis (SSc) (46/50 responders in a multicentric European study with 35% of relapses and 23% of mortality, while in an US series, 4/19 patients died, 2 had progressive lung disease and all the survivors improved the skin scores and quality of life) and several other diseases, including vasculidities (9/15 complete responses in the European registry). We conclude that in the international experience, autologous HSCT induces sustained remission in most severe and refractory rheumatic diseases except for adult rheumatoid arthritis, and this finding justifies starting prospective randomized trials of HSCT compared to optimal conventional therapy.
8183 downloads
Showing
itens per page
Page
of 1
Next
Statistics of
Send result
Sem resultados
No documents were found for your search
Glossary and search help
You can enrich your search in a very simple way. Use the search indexes combined with the connectors (AND or OR) and specify more your search.
For example, if you want to search for articles about
cases of dengue in Brasil in 2015, use:ti:dengue and publication_year:2015 and aff_country:Brasil
See below the complete list of search indexes that can be used:
Index code | Element |
---|---|
ti | article title |
au | author |
kw | article keywords |
subject | subject (title words, abstract and keywords) |
ab | abstract |
ta | journal short title (e.g. Cad. Saúde Pública) |
journal_title | journal full title (e.g. Cadernos de Saúde Pública) |
la | publication language code (e.g. pt - Portuguese, es - Spanish) |
type | document type |
pid | publication identifier |
publication_year | publication year of publication |
sponsor | sponsor |
aff_country | country code of the author's affiliation |
aff_institution | author affiliation institution |
volume | article volume |
issue | article issue |
elocation | elocation |
doi | DOI number |
issn | journal ISSN |
in | SciELO colection code (e.g. scl - Brasil, col - Colômbia) |
use_license | article usage license code |